Clinical Trial Detail

NCT ID NCT01487265
Title Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

lung non-small cell carcinoma

Therapies

Buparlisib + Erlotinib

Age Groups: adult senior

No variant requirements are available.